PROGRESS OF DEVELOPMENT

Disclosuring of information after Phase 3

DrugDosage FormPropertyIndicationStatus (Region)
DifluprednateEye dropCorticosteroidsinflammation associated with ocular surgery, UveitisNDA (Russia)
As of December 2021